Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Manto Papageorgiou"'
Publikováno v:
International Journal for Equity in Health, Vol 16, Iss 1, Pp 1-9 (2017)
Abstract Background Evidence suggests that Greece is among the European countries with increased trend in HCV prevalence among injecting drug users (IDUs) from 2008 to 2014. Nonetheless, the access of IDUs to treatment for Hepatitis C Virus (HCV) is
Externí odkaz:
https://doaj.org/article/e3d57837e26d4b00a0c6d46b3871bb39
Autor:
Kyriakos Souliotis, Elena Alexopoulou, Manto Papageorgiou, Anastasia Politi, Panagiota Litsa, Xenophon Contiades
Publikováno v:
International Journal of Health Policy and Management, Vol 5, Iss 2, Pp 83-89 (2016)
Background While there is currently no cure for multiple sclerosis (MS), treatment with biologic diseasemodifying drugs (bDMDs) can reduce the impact of the condition on the lives of patients. In Greece, the regulatory change in the distribution syst
Externí odkaz:
https://doaj.org/article/83c022d1447741b28a77e1d048d68819
Publikováno v:
Frontiers in Public Health, Vol 4 (2016)
Background: Affordable, accessible and innovation-promoting pharmaceutical care is essential to the operation of a sustainable health system. External reference pricing (ERP), a common pharmaceutical policy in Europe, suffers today from indigenous we
Externí odkaz:
https://doaj.org/article/496dc1dc1cd34e14809b62fc94a51417
Autor:
Kyriakos Souliotis, Chara Kani, Manto Papageorgiou, Dimitrios Lionis, Konstantinos Gourgoulianis
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0154960 (2016)
INTRODUCTION:Chronic Obstructive Pulmonary Disease (COPD) is one of the top leading causes of death and disability, and its management is focused on reducing risk factors, relieving symptoms, and preventing exacerbations. The study aim was to describ
Externí odkaz:
https://doaj.org/article/929f4bdfc0054217bf999f0cb96bfe5e
Autor:
Maria Saridi, Ioannis Kalemikerakis, Kyriakos Souliotis, Manto Papageorgiou, Athena Kalokerinou
Publikováno v:
Wound Repair and Regeneration. 24:596-601
The aim of the study was a cost and clinical effectiveness analysis between moist wound healing dressings and gauze in a homecare set up for the treatment of stage III and IV pressure ulcers up to complete healing. In addition, we assessed the overal
Autor:
Panagiota Litsa, Kyriakos Souliotis, Xenophon Contiades, Anastasia Politi, Manto Papageorgiou, Elena Alexopoulou
Publikováno v:
International Journal of Health Policy and Management, Vol 5, Iss 2, Pp 83-89 (2016)
Background While there is currently no cure for multiple sclerosis (MS), treatment with biologic diseasemodifying drugs (bDMDs) can reduce the impact of the condition on the lives of patients. In Greece, the regulatory change in the distribution syst
Publikováno v:
Value in health regional issues. 2(2)
ObjectiveThe Greek Public Servants’ Health Care Organization aiming to organize, monitor, and enhance the health care services provided to 1,500,000 public servants decided to respond to the national alert of the economic crisis through the reducti
Healthcare access for cancer patients in the era of economic crisis. Results from the HOPE III study
Publikováno v:
Forum of Clinical Oncology, Vol 6, Iss 4, Pp 7-11 (2015)
Background: Despite the documentation of addressing healthcare disparities in detection and treatment of cancer and health outcomes for cancer patients, the inequalities persist. Cancer patients of several vulnerable groups suffer disproportionally t
Autor:
Anastasia Politi, Prodromos Sidiropoulos, Kyriakos Souliotis, Manto Papageorgiou, Dimitrios Ioakeimidis
Publikováno v:
Rheumatology International. 34:25-33
The latest regulatory change in the distribution system of biologic disease-modifying, antirheumatic drugs limited their sale only through the designated pharmacies of the National Organization for Healthcare Services Provision (EOPYY) or the Nationa
Publikováno v:
Frontiers in Public Health
Frontiers in Public Health, Vol 4 (2016)
Frontiers in Public Health, Vol 4 (2016)
Background Affordable, accessible, and innovation-promoting pharmaceutical care is essential to the operation of a sustainable health system. External reference pricing (ERP), a common pharmaceutical policy in Europe, suffers today from indigenous we